Klaria Pharma Holding AB (FRA:6FN) ROCE %: 0.00% (As of Mar. 2026)

What is Klaria Pharma Holding AB ROCE %?

Klaria Pharma Holding AB FRA:6FN -8.28% 28 ROCE % is 0.00% as of Mar. 2026. GuruFocus rates FRA:6FN with a GF Score™ of 28/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Klaria Pharma Holding AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.00%.

Klaria Pharma Holding AB (FRA:6FN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Klaria Pharma Holding AB ROCE % Related Terms

Klaria Pharma Holding AB ROCE % Historical Data

* Premium members only.

The historical data trend for Klaria Pharma Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klaria Pharma Holding AB ROCE % Chart

Klaria Pharma Holding AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-55.94

-73.54

-54.13

-135.04

-11,307.32

Klaria Pharma Holding AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															395.65	0.00	0.00	-3,072.19	0.00

28GF Score

Klaria Pharma Holding AB FRA:6FN

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Klaria Pharma Holding AB ROCE % Calculation

Klaria Pharma Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-2.318	/	( ( (4.979 - 4.638)	+	(3.746 - 4.046) )	/ 2 )
	=	-2.318	/	( (0.341	+	-0.3)	/ 2 )
	=	-2.318	/	0.0205
	=	-11,307.32 %

Klaria Pharma Holding AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-2.676	/	( ( (3.746 - 4.046)	+	(2.786 - 3.799) )	/ 2 )
	=	-2.676	/	( ( -0.3	+	-1.013 )	/ 2 )
	=	-2.676	/	-0.6565
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 0.00% mean?

Klaria Pharma Holding AB (FRA:6FN) has a ROCE % of 0.00% as of Mar. 2026.

Is Klaria Pharma Holding AB's ROCE % too high?

Klaria Pharma Holding AB's current ROCE % is 0.00%. Overall, Klaria Pharma Holding AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Klaria Pharma Holding AB's ROCE % compare to ZTS and UTHR?

Klaria Pharma Holding AB's ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klaria Pharma Holding AB's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Klaria Pharma Holding AB stock overvalued right now?

Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.06 — trading 99.3% above its estimated fair value. The current ROCE % is 0.00%. Klaria Pharma Holding AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current ROCE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 99.3% above its estimated GF Value™ of €0.03. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

ROCE %: 0.00%
GF Value™: €0.03 vs. price of €0.06 (99.3% above fair value)
GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Klaria Pharma Holding AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XSAT:ACUC OSTO:VIVE OSTO:NEWBRY XSAT:ODI XSAT:PMED OSTO:GABA OSTO:ERMA OSTO:MOB OSTO:CINPHA OSTO:ENZY XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges KLAR:Sweden

Address Virdings Alle 2, Uppsala, CHE, 754 50

Website https://www.klaria.com

Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.

28GF Score

Get the complete analysis for FRA:6FN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06

Price

€0.03

GF Value

View FRA:6FN Analysis

See ROCE % data for all stocks →